Business Description
Novavax Inc
NAICS : 325414
SIC : 2836
ISIN : US6700024010
Total Employee Number:
749Compare
Compare
Traded in other countries / regions
NVAX.USANVV1.GermanyNVAX.AustriaNVAX.MexicoNVV1.BulgariaNVAX.Switzerland IPO Date
2025-12-01Description
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.68 | |||||
Equity-to-Asset | -0.14 | |||||
Debt-to-Equity | -2.04 | |||||
Debt-to-EBITDA | -7 | |||||
Interest Coverage | 0.91 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -4.41 | |||||
Beneish M-Score | -2.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -31.8 | |||||
3-Year FCF Growth Rate | 39.4 | |||||
3-Year Book Growth Rate | 52.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -32.38 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.25 | |||||
9-Day RSI | 54.95 | |||||
14-Day RSI | 53.45 | |||||
3-1 Month Momentum % | 25.12 | |||||
6-1 Month Momentum % | 30.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.48 | |||||
Quick Ratio | 2.45 | |||||
Cash Ratio | 2.31 | |||||
Days Inventory | 46.44 | |||||
Days Sales Outstanding | 53.23 | |||||
Days Payable | 114.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.6 | |||||
Shareholder Yield % | -1.59 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 84.97 | |||||
Operating Margin % | 3.3 | |||||
Net Margin % | -14.73 | |||||
EBITDA Margin % | -7.06 | |||||
FCF Margin % | -16.67 | |||||
OCF Margin % | -15.66 | |||||
ROA % | -7.28 | |||||
ROIC % | 3.46 | |||||
3-Year ROIIC % | -70.9 | |||||
ROC (Joel Greenblatt) % | -41.43 | |||||
ROCE % | -8.09 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 47.7 | |||||
PS Ratio | 2.73 | |||||
EV-to-EBIT | -16.17 | |||||
EV-to-EBITDA | -24.74 | |||||
EV-to-Revenue | 1.75 | |||||
EV-to-Forward-Revenue | 2.7 | |||||
EV-to-FCF | -10.68 | |||||
Price-to-GF-Value | 2.42 | |||||
Price-to-Median-PS-Value | 0.23 | |||||
Earnings Yield (Greenblatt) % | -6.18 | |||||
FCF Yield % | -6.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novavax Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 477.725 | ||
| EPS (TTM) (CHF) | -0.45 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 53.45 | ||
| 14-Day ATR (CHF) | 0.169555 | ||
| 20-Day SMA (CHF) | 7.3291 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (CHF) | 5.72 - 8.97 | ||
| Shares Outstanding (Mil) | 164.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novavax Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novavax Inc Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 123 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 122 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | In 31 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 30 days | ||
| General meeting for 2026 | 2026-06-18 08:30 | 7.41 (+0.00%) | ||
| Guidance call for 2026 | 2026-06-04 10:30 | 8.01 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:30 | 6.31 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 6.31 (+0.00%) | ||
| Guidance call for 2026 | 2026-03-10 15:40 | 7.98 (+0.00%) | ||
| TD Cowen 46th Annual Health Care Conference: | 2026-03-03 14:30 | 7.75 (+0.00%) |
Show
Entries
Novavax Inc Frequently Asked Questions
What is Novavax Inc(XSWX:NVAX)'s stock price today?
The current price of XSWX:NVAX is CHF7.61. The 52 week high of XSWX:NVAX is CHF8.97 and 52 week low is CHF5.72.
When is next earnings date of Novavax Inc(XSWX:NVAX)?
The next earnings date of Novavax Inc(XSWX:NVAX) is 2026-08-06 Est..
Does Novavax Inc(XSWX:NVAX) pay dividends? If so, how much?
Novavax Inc(XSWX:NVAX) does not pay dividend.
Press Release
Articles on Novavax Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers